Pharvaris BV (PHVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharvaris BV (PHVS) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.67 Million) by net assets ($312.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PHVS equity to assets ratio to measure how much of total assets are equity-financed.
Pharvaris BV - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Pharvaris BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PHVS debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Pharvaris BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharvaris BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Watsco Inc
NYSE:WSO-B
|
-0.006x |
|
ZAI LAB LTD0000006
F:1ZLB
|
-0.018x |
|
Tongyu Communication Inc
SHE:002792
|
0.032x |
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
Grupo Mateus S.A
SA:GMAT3
|
0.056x |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
0.165x |
|
Lakala Payment Co Ltd
SHE:300773
|
0.035x |
|
Great Microwave Technology Co. Ltd. A
SHG:688270
|
0.005x |
Annual Cash Flow Conversion Efficiency for Pharvaris BV (2018–2024)
The table below shows the annual cash flow conversion efficiency of Pharvaris BV from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see PHVS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $267.76 Million | $-120.13 Million | -0.449x | -85.17% |
| 2023-12-31 | $384.05 Million | $-93.05 Million | -0.242x | +46.16% |
| 2022-12-31 | $149.26 Million | $-67.16 Million | -0.450x | -106.78% |
| 2021-12-31 | $204.95 Million | $-44.60 Million | -0.218x | +3.05% |
| 2020-12-31 | $95.79 Million | $-21.50 Million | -0.224x | +37.23% |
| 2019-12-31 | $18.67 Million | $-6.68 Million | -0.358x | +54.81% |
| 2018-12-31 | $4.95 Million | $-3.92 Million | -0.791x | -- |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more